Tofacitinib em Artrite Psoriásica: Sinais e Sintomas e Qualidade de Vida Relacionada à Saúde em dois Estudos Randomizados de Fase 3
J Eur Acad Dermatol Venereol 2020;34:2809–2820.
Considering the multi-domain nature of PsA, effective treatments must demonstrate efficacy across a range of clinical and patient-reported outcomes. Dermatologic symptoms often precede rheumatic manifestations in people with PsA, typically by 10 years. Tofacitinib demonstrated significant improvements across a range of outcomes including burdensome dermatologic symptoms. This post hoc analysis included data from two double-blind, Phase 3 studies in patients with active PsA and an inadequate resp...